Cantourage is a publicly listed, leading European medical cannabis company. The Berlin-based company with subsidiaries in the United Kingdom and Poland, was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. Cantourage enables producers from all over the world to become part of the rapidly growing European medical cannabis market in a faster and more cost-effective way, while guaranteeing and developing the highest European quality standards. The company offers products in all relevant market segments: dried flowers, extracts, Dronabinol and pharma-grade Cannabidiol. The company was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under the stock ticker “HIGH”.
First trading day | 11/11/2022 |
Securities identification number | A3DSV0 |
ISIN | DE000A3DSV01 |
LEI | 3912003NCTLO6YHA9V48 |
Ticker Symbol | HIGH |
Segment | Scale |
Market | Open Market |
Trading venues | XETRA, Frankfurt (Scale), Open Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
Class of shares | Bearer shares |
Share capital in EUR | 12,467,479.00 |
Number of shares | 12,467,479 |
Designated Sponsor | Hauck Aufhäuser/mwb fairtrade Wertpapierhandelsbank, both Frankfurt am Main |
Specialist | WOLFGANG STEUBING AG |
Paying agent | Hauck Aufhäuser Lampe Privatbank AG, Kaiserstrasse 24, 60311 Frankfurt am Main |
Financial year | 1 January to 31 December |
This announcement does not constitute a public offer or an advertisement for a public offer within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company's financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as "Relevant Persons"). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.